Form 4: Director Azab Granted LSTA Restricted Stock Units

Lisata Therapeutics Director Mohammad Azab was granted 30,456 restricted stock units, vesting in January 2027.

Summary

• Mohammad Azab, a Director of Lisata Therapeutics, Inc. (LSTA), acquired 30,456 shares of Common Stock.
• This acquisition was a grant of restricted stock units (RSUs) under the Issuer's 2018 Equity Incentive Compensation Plan.
• The RSUs were granted on January 9, 2026, and are scheduled to vest on January 9, 2027.
• Following this transaction, Mohammad Azab beneficially owns a total of 104,925 shares, which includes these 30,456 unvested restricted stock units.
• The transaction price for these RSUs was $0, as is typical for grants.

Sentiment

Score: 6

Explanation: The filing reports a routine insider equity grant as part of a compensation plan. This is a neutral to slightly positive event as it aligns director interests with shareholders, but it does not indicate significant operational or financial news.

Positives

• The grant of 30,456 restricted stock units to Director Mohammad Azab aligns his interests with those of shareholders, incentivizing long-term performance.
• The equity grant is part of the company's 2018 Equity Incentive Compensation Plan, indicating a structured approach to executive compensation.

Negatives

• The acquired shares are restricted stock units and do not provide immediate liquidity or full ownership until they vest on January 9, 2027.
• The value of the compensation is tied directly to the future stock price of Lisata Therapeutics, Inc., introducing market risk.

Risks

• Vesting Risk: The 30,456 restricted stock units are subject to a vesting period and will not be fully owned until January 9, 2027, meaning the director must remain with the company for the shares to vest.
• Market Price Risk: The ultimate value of the compensation is dependent on the market price of Lisata Therapeutics, Inc. (LSTA) common stock at the time of vesting, which can fluctuate.

Future Outlook

The grant of restricted stock units implies a future ownership stake for Director Mohammad Azab upon their vesting on January 9, 2027, aligning his long-term interests with the company's performance.

Industry Context

The grant of restricted stock units to a director is a standard practice for executive compensation across many industries, particularly in biotechnology and pharmaceuticals, aiming to align management incentives with shareholder value creation.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) as a form of equity compensation to a director is a common practice within the industry, consistent with global benchmarks for executive incentive programs.
• The filing does not provide specific details on comparable companies, projects, or results to allow for a direct quantitative comparison of the grant size or terms.

Corporate Governance

Related Party Transactions

• The grant of 30,456 restricted stock units to Mohammad Azab, a Director of Lisata Therapeutics, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board. This is a standard form of executive compensation.

Stakeholder Impact

• Shareholders: The grant aligns the director's long-term interests with shareholder value creation, potentially leading to more focused leadership. It also represents potential future dilution upon vesting, though typically planned for in equity compensation plans.
• Management/Employees: This transaction is a form of compensation for a director, reflecting the company's approach to incentivizing its leadership.

Next Steps

• Vesting of the 30,456 restricted stock units on January 9, 2027, at which point they will convert to fully owned common stock.

Key Dates

Keywords

Lisata Therapeutics, LSTA, Mohammad Azab, Form 4, Restricted Stock Units, RSU, Equity Incentive Plan, Director Compensation, Insider Transaction